Trial Profile
A Phase III Double Blinded, Randomized Controlled Study to Evaluate Efficacy of Protection Against HPV-16 and 18 Related Diseases, Immunogenicity and Safety of HPV-16/18 Vaccine in Healthy Females Aged 18-30 Years
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2022
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
- Indications Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Registrational; Therapeutic Use
- Sponsors Shanghai Zerun Biotechnology Co
- 16 Dec 2022 Status changed from active, no longer recruiting to completed.
- 20 Apr 2016 New trial record